Key result
Human cytomegalovirus seropositivity shows no link to incident CVD or all-cause mortality.
Why the study?
Human cytomegalovirus seropositivity has shown varying levels of association with cardiovascular disease and all-cause mortality in previous studies.
Does human cytomegalovirus seropositivity increase the risk of incident cardiovascular disease, ischaemic heart disease, stroke, and all-cause mortality in middle-aged to older adults?
Cohort (n=8,740)
Yes
Does human cytomegalovirus seropositivity increase the risk of incident cardiovascular disease, ischaemic heart disease, stroke, and all-cause mortality in middle-aged to older adults?
Answers are grounded in this paper and cite their sources.
Human cytomegalovirus seropositivity is not independently associated with an increased risk of cardiovascular disease, ischaemic heart disease, stroke, or all-cause mortality when adjusting for relevant sociodemographic and health-related confounders.
Human cytomegalovirus seropositivity has shown varying levels of association with cardiovascular disease and all-cause mortality in previous studies. This study uses updated data from the UK Biobank to test these associations. The association between human cytomegalovirus seropositivity and outcomes of incident cardiovascular disease, ischaemic heart disease, stroke and all-cause mortality was determined using multivariate Cox proportional-hazards models in 8740 UK Biobank participants aged 40-69 years. Two directed acyclic graphs depicting the hypothesized relationship between human cytomegalovirus infection (either in childhood or adulthood) and cardiovascular disease/all-cause mortality controlled the selection of biological and socioeconomic confounders to be adjusted for in each model. Human cytomegalovirus seropositivity was not significantly associated with cardiovascular disease, ischaemic heart disease, stroke or all-cause mortality when applying either the fully adjusted adulthood or childhood infection models. We found no significant association between human cytomegalovirus seropositivity and any of the measured outcomes. Further research is expected to include larger sample sizes, younger participants and more ethnically diverse cohorts.This article is part of the discussion meeting issue 'The indirect effects of cytomegalovirus infection: mechanisms and consequences'.
No takes yet. Share an insight, caveat, or question.
Doorly et al. (2025) conducted a cohort in Cardiovascular disease (n=8,740). Human cytomegalovirus (HCMV) seropositivity vs. HCMV seronegativity was evaluated on Incident cardiovascular disease (CVD) events (HR 1.00, 95% CI 0.86-1.15). Human cytomegalovirus seropositivity was not associated with incident cardiovascular disease or all-cause mortality in fully adjusted models.
Synapse has enriched 10 related papers. Consider them for comparative context: